GlassScriptPhysician profile
Charles Edward Jacocks
NPI 1104321967
$796.97
in general payments reported to CMS, 2019-2025
14 companies · $22.26 in 2025
The $22.26 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.93 · 2020: $76.12 · 2021: $86.76 · 2022: $58.70 · 2024: $479 · 2025: $22.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $217.33 | 2024 | |
| Genmab U.S., INC. | $132.50 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $129.37 | 2024 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.98 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $47.01 | 2021 | |
| Grt US Holding, INC. | $33.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.35 | 2022 | |
| Vifor Pharma, INC. | $19.23 | 2022 | |
| Abbvie INC. | $16.82 | 2020 | |
| Abbott Laboratories | $16.75 | 2019 | |
| Chiesi USA, INC. | $15.79 | 2020 | |
| Pfizer INC. | $15.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Jacocks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.